Compare · ELDN vs JNJ
ELDN vs JNJ
Side-by-side comparison of Eledon Pharmaceuticals Inc. (ELDN) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELDN and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 3309.0x ELDN ($184.5M).
- Over the past year, ELDN is down 38.0% and JNJ is up 32.3% - JNJ leads by 70.2 points.
- JNJ has been more active in the news (16 items in the past 4 weeks vs 2 for ELDN).
- JNJ has more recent analyst coverage (25 ratings vs 4 for ELDN).
- Company
- Eledon Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $2.13-5.75%
- $255.53+0.88%
- Market cap
- $184.5M
- $610.38B
- 1M return
- -19.47%
- -5.45%
- 1Y return
- -37.99%
- +32.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 2
- 16
- Recent ratings
- 4
- 25
Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ELDN
- Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
- Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
- Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
- SEC Form S-8 filed by Eledon Pharmaceuticals Inc.
- Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
- SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.
- Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Chief Executive Officer Gros David-Alexandre C was granted 354,454 shares and covered exercise/tax liability with 194,791 shares, increasing direct ownership by 1,774% to 168,663 units (SEC Form 4) (withholding tax)
- President Perrin Steven was granted 152,353 shares and covered exercise/tax liability with 72,138 shares, increasing direct ownership by 8,022% to 81,215 units (SEC Form 4) to cover withholding tax
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause